Company Filing History:
2 out of 199 
2 out of 5,506 
1 out of 9 Years Active: 2004-2012
Title: Martin J McGavin: Innovator in Antibody Research
Introduction
Martin J McGavin is a notable inventor based in Etobicoke, Canada. He has made significant contributions to the field of antibody research, particularly in the development of antibodies that block the binding of fibronectin protein. With a total of 3 patents, his work has implications for various medical applications.
Latest Patents
McGavin's latest patents focus on antibodies that inhibit the binding of fibronectin protein to fibronectin. These patents also disclose site specifically-mutated and truncated peptide epitopes derived from the fnbA and fnbB genes, as well as the sfb gene. The anti-fibronectin binding site antibodies, peptides, and epitopes are designed to block the binding of fibronectin binding proteins to fibronectin. These innovations are useful in screening, diagnostic, and therapeutic applications, including immunization methods to prevent streptococcal and staphylococcal colonization in both animals and humans. Furthermore, the DNA segments and peptides derived from these innovations are proposed for use in vaccine preparation and as carrier proteins in vaccine formulations.
Career Highlights
Throughout his career, McGavin has worked with esteemed institutions such as the University of Manitoba and Texas A&M University System. His research has contributed to advancements in immunology and vaccine development.
Collaborations
Some of McGavin's notable coworkers include Joseph M Patti and Karen L House-Pompeo. Their collaborative efforts have furthered research in the field of antibody development.
Conclusion
Martin J McGavin's innovative work in antibody research has led to significant advancements in medical applications, particularly in vaccine development. His contributions continue to impact the field positively.